Camp4 Therapeutics Corp

Listed Company

CAMPCIK 0001736730NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.50M

Net Income

$-80.40M

Total Assets

$117.81M

Equity

$47.70M

Shares Out

51.92M

Op. Cash Flow

$-29.60M

Business

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company that discovers and develops a new class of RNA-based therapeutics that upregulate gene expression by targeting regulatory RNAs (regRNAs). It develops sequence-specific antisense oligonucleotide (ASO) products, called RNA Actuators, including clinical-stage CMP-CPS-001 and development candidate CMP-SYNGAP-01, and discovery programs such as GBA1. Its key business activities comprise its proprietary RAP Platform for regRNA mapping and ASO screening, therapeutic programs focused on metabolic and CNS disorders, and strategic collaborations. It conducts clinical trials internationally, uses subcutaneous GalNAc conjugation for liver delivery and intrathecal delivery for CNS, and relies on third-party manufacturers and distribution partners.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research and collaboration revenue	3	652,000	350,000
Research and development	38	39	41
General and administrative	17	15	12
Impairment of right-of-use asset	494,000	0	—
Total operating expenses	56	54	52
Loss from operations	−53	−53	−52
Interest income	2	1	3
Change in fair value of derivative tranche liability	−30	0	—
Other expense	−192,000	−33,000	−220,000
Total other (expense) income, net	−28	1	3
Net loss	−80	−52	−49
Net loss per share attributable to common stockholders, basic, (in USD per share)	−2.65	−11.04	−124.8
Net loss per share attributable to common stockholders, diluted, (in USD per share)	−2.65	−11.04	−124.8
Weighted-average shares of common stock outstanding, basic, (in shares)	30	5	394,976
Weighted-average shares of common stock outstanding, diluted, (in shares)	30	5	394,976
Other comprehensive income (loss)	0	0	—
Total comprehensive loss	−80	−52	−49

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	110	64	38	—
Restricted cash, current portion	1	0	—	—
Prepaid expenses and other current assets	3	2	2	—
Total current assets	114	66	40	—
Restricted cash, net of current portion	894,000	2	2	—
Property and equipment, net	2	4	—	—
Operating lease right-of-use assets	397,000	6	8	—
Other assets	83,000	427,000	—	—
Total assets	118	78	55	—
Accounts payable	182,000	1	1	—
Accrued expenses and other current liabilities	6	5	3	—
Current portion of deferred revenue	9	385,000	0	—
Operating lease liabilities, current portion	286,000	3	3	—
Other current liabilities	27,000	176,000	—	—
Total current liabilities	16	10	8	—
Deferred revenue, net of current portion	8	0	—	—
Operating lease liabilities, net of current portion	2	5	8	—
Derivative tranche liability	45	0	—	—
Other liabilities	29,000	72,000	2,000	—
Total liabilities	70	15	17	—
Commitments and contingencies (Note 7)	—	—	—	—
Common stock, $0.0001 par value per share; 175,000,000 shares authorized as of December 31, 2025 and 2024; 51,902,614 issued and outstanding as of December 31, 2025; 20,161,073 and 20,145,129 shares issued and outstanding as of and December 31, 2024, respectively	6,000	2,000	1,000	—
Additional paid-in capital	340	275	36	—
Accumulated deficit	−292	−212	−160	—
Total stockholders equity	48	63	−124	−78
Total liabilities and stockholders equity	118	78	55	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation and amortization	2	2	2
Stock-based compensation expense	4	4	3
Loss on the sale of property and equipment	258,000	0	—
Non-cash gain on lease modification	−316,000	0	—
Non-cash lease expense	2	2	—
Non-cash interest expense	16,000	83,000	92,000
Prepaid expenses and other current assets	−888,000	−711,000	−420,000
Accounts payable	−1	168,000	−1
Accrued expenses and other liabilities	805,000	2	−136,000
Operating lease assets and liabilities	−3	−3	402,000
Deferred revenue	17	385,000	0
Net cash used in operating activities	−30	−46	−44
Purchases of property and equipment	−279,000	−441,000	−678,000
Proceeds from the sale of property and equipment	36,000	0	—
Net cash used in investing activities	−243,000	−441,000	−678,000
Proceeds from issuance of common stock, net of issuance costs of $3,966 and $5,747, respectively	58	76	0
Proceeds from issuance of pre-funded warrants, net of issuance costs $258	4	0	—
Proceeds allocated to the derivative tranche liability	15	0	—
Proceeds from exercise of common stock options	51,000	113,000	700,000
Principal payments on financing obligation	−97,000	−460,000	−268,000
Principal payments on finance leases	−111,000	−364,000	−322,000
Payments of deferred issuance costs	0	−4	—
Net cash provided by financing activities	76	72	301,000
Net increase in cash, cash equivalents and restricted cash	46	26	−45
Conversion of convertible preferred stock upon initial public offering	0	162	0
Finance lease right-of-use asset converted to fixed asset	290,000	127,000	0
Issuance costs in accounts payable and accrued expenses	203,000	0	12,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro